

Coumarin: a potential nucleus for anti-inflammatory molecules

Yogita Bansal · Purva Sethi · Gulshan Bansal

Received: 4 August 2012 / Accepted: 25 October 2012 / Published online: 10 November 2012
© Springer Science+Business Media New York 2012

Abstract Numerous research reports have indicated the coumarin nucleus as a potential candidate for development of anti-inflammatory drugs. Various phytoconstituents such as umbelliferone, scopoletin, columbinetin, visniadin, marmin, and many more derived from coumarin nucleus are found to have potent anti-inflammatory as well as antioxidant activities. A large number of coumarin derivatives have also been designed, synthesized, and evaluated to have mild-to-very potent anti-inflammatory activity through different mechanisms. However, despite the continuing efforts in search of these drugs, no major breakthrough has been achieved so far. In the present review, a critical analysis of various reports on naturally as well as the synthetically derived coumarin derivatives having anti-inflammatory activity has been carried out and a structural–activity relationship around the coumarin nucleus has been proposed to assist the medicinal chemists in rationally designing the anti-inflammatory drugs.

Keywords Coumarin · Anti-inflammatory · Structure–activity relationship · TNF α inhibitor

Introduction

Inflammation is a dynamic biological process which occurs as a result of chemical, physical, immunological, and/or biological stimuli to human body (Khan *et al.*, 2005). It is characterized by five cardinal signs i.e., *rubor* (redness), *tumor* (swelling), *calore* (heat), *dolore* (pain), and *function*

laesa (disturbance of function) (Medzhitov, 2011). The four components of a typical inflammatory process include inflammatory inducers (like infection, wound or tissue injury, or any other diseased state), sensors (like mast cells, macrophages, dendritic cells, etc.), inflammatory mediators (like various cytokines, biological amines, etc.), and the target tissues (Dinarello, 2010). A moderate inflammation is essentially an adaptive response of human body to restore the homeostasis through countering the antigens/inducers by phagocytosis or immigration of leukocytes at the site of injury. This acute inflammatory response is normally terminated (resolution of inflammation) after the inducer is eliminated (Li *et al.*, 2011). However, if inducer is not eliminated or persists because of any diseased states, such as Alzheimer's disease, asthma, atherosclerosis, Crohn's disease, gout, multiple sclerosis, osteoarthritis, psoriasis, rheumatoid arthritis, diabetes mellitus, carcinoma, bacterial or viral infections, etc., then the resolution phase may not be induced leading to chronic inflammation (Kontogiorgis and Hadjipavlou-Litina, 2005; Symeonidis *et al.*, 2009) usually localized to the site of inducers and results in local tissue remodeling. Such chronic inflammatory states generate a vicious cycle between inflammation and the accompanying pathological state. For instance, obesity can lead to inflammation, and the chronic inflammation can promote obesity-associated diabetes by inducing insulin resistance (Grivennikov *et al.*, 2010). Therefore, control of inflammation becomes more important in all pathological conditions, and it has occupied a central position in many branches of pharmacology.

The inflammatory response can be controlled by eliminating the inducers, by blocking the sensors, by inhibiting the mediators, or by directly acting on the target tissues (Medzhitov, 2008). Elimination of inducer, especially diseased states mentioned earlier, may need long-term drug

Y. Bansal (✉) · P. Sethi · G. Bansal
Department of Pharmaceutical Sciences and Drug
Research, Punjabi University, Patiala 147002, India
e-mail: yogitabansalp@rediffmail.com

treatments, and in such cases, control of inflammation by the use of anti-inflammatory agents becomes important to prevent tissue remodeling (Nathan, 2002). The most widely explored targets for controlling inflammation are the inflammatory mediators such as plasma proteases, arachidonic acid metabolites (like PGE2 and leukotrienes), histamine, serotonin, nitric oxide, cytokines (such as lipoxins, interleukins 1–16, and tumor necrosis factor- α), chemokines (such as those belonging to the CXC, CC, and C subsets), and colony-stimulating factors (CSFs) (Khan *et al.*, 2010; Cronstein and Weissmann, 1995). These mediators are produced through various processes involving cyclooxygenases, caspases, and kinases (like cyclin-dependent kinases, mitogen-activated protein kinase 38, c-jun N-terminal kinase, mitogen-activated protein kinase/extracellular signal regulated kinase, serine threonine kinases, interleukin receptor-associated kinase 4, Janus kinases, kinase insert domain receptor, NF- κ B, lymphocyte specific kinase, spleen tyrosine kinase, and TNF α kinase as result of activation of sensors cells and bind to specific receptor to orchestrate the inflammatory response (Bhagwat, 2009; Feghali and Wright, 1997; Sebba and Courtois, 2006)).

A large number of chemical compounds derived from diverse group of heterocyclic nuclei are reported to inhibit inflammatory process at one or the other stage. Coumarin analogs constitute an important class of anti-inflammatory molecules. Many research groups have reported that various coumarin derivatives block inflammation at various levels as depicted in Fig. 1. However, no such molecule has made its way to the clinics so far. Fylaktakidou *et al.* (2004) have reviewed various natural and synthetic coumarin derivatives as anti-inflammatory and antioxidant molecules. Curini *et al.* (2006) have also reviewed the biological potential of prenyloxycoumarins and prenyloxyfuranocoumarins which are generally considered as a family of secondary plant metabolites only used as intermediates in coumarin-based compounds. The present review is a comprehensive update and critical analysis of various reports on naturally as well as synthetically derived coumarin derivatives till date having anti-inflammatory activity culminating to structural–activity relationships (SARs). These SARs around the coumarin template may help medicinal chemists in designing and synthesizing novel compounds with improved anti-inflammatory and other pharmacological activities.

Naturally derived coumarin derivatives

Flavonoids constitute an important class of coumarin-based phytoconstituents and are found in abundant amounts in




Fig. 1 Inflammatory targets of coumarin derivatives

essential oils, fruits, green tea, and other foods such as chicory (Lake, 1999; Lacy and Kennedy, 2004). The richest sources of coumarin-based molecules are the plants of Rutaceae and Umbelliferae families. Although distributed throughout all parts of the plant, their maximum contents are found in fruits, followed by roots, stems, and leaves (Keating and Kennedy, 1997). Various coumarin derivatives isolated from plants (Table 1) have been reported to possess anti-inflammatory activities. These act by reducing tissue edema, altering the functions of enzymatic systems, such as cyclooxygenase and lipoxygenase, and preventing the generation of free radicals. A detailed analysis of structures of these coumarin-based constituents has helped in postulating a brief SAR around the coumarin nucleus (Table 1):

- An α,β -unsaturated carbonyl group or free hydroxyl at the C-8 increases the activity.
- Most of the constituents are 6-/7-monosubstituted, 6, 7-disubstituted, or 6,7-fused coumarins. In general, any substituent at any of these two positions are found to contain an oxygen atom ($-\text{OH}$ or $-\text{OR}$). Hence, a polar moiety is very well tolerated at these positions.
- The C-4 remains unsubstituted in all the plant-derived coumarins.
- A linear long chain hydrophobic moiety is well tolerated at C-3.

Synthetically derived coumarins derivatives

Many reports on synthesis and exploration of numerous coumarin analogs for anti-inflammatory, analgesic, and/or antioxidant activities are available in the literature. These are discussed in chronological order herein. One of the

Table 1 Coumarin-based anti-inflammatory phytoconstituents












Source	Chemical constituent	References
Hydroalcoholic extract from aerial part of <i>Justicia pectoralis</i>	 <p>Umbelliferone</p>	Lino <i>et al.</i> , (1997)
Ethyl acetate extract of <i>Santolina oblongifolia</i>	 <p>Aesculetin Scopolin Herniarin Scopoletin</p>	Silvan <i>et al.</i> , (1998)
Aqueous extract of <i>Corydalis heterocarpa</i>	 <p>Columbianetin Libonoridin</p>	Kang <i>et al.</i> , (2009)
Petroleum benzene/ acetoacetate fraction of powdered stems of <i>Erycibe obtusifolia</i>	 <p>Scopoletin</p>	Pan <i>et al.</i> , (2010)
Dry extract of aerial parts of <i>Lingusticum lucidum</i>	 <p>Praeruptorin Visnadin</p>	Menghini <i>et al.</i> , (2010)

Table 1 continued

Source	Chemical constituent	References
Aqueous infusion of aerial parts of <i>Bidens tripartite</i>	 <p>Fraxetin Daphnetin</p>	Pozharitskaya <i>et al.</i> , (2010)
Extract from roots of <i>Ferula fukanensis</i>	 <p>Fukanemerin</p>	Nazari and Ironshahi (2011)
<i>n</i> -Hexane extract of aerial parts and roots of <i>Zosima absinthifolia</i>	 <p>(+)-Columbiandin (-)-Deltoin</p>	Bahadir <i>et al.</i> , (2011)
Roots of <i>Aegle marmelos</i> and <i>H. laciniatum</i>	 <p>Marmin Sphondin</p>	Shoeb <i>et al.</i> , (1973), Ling <i>et al.</i> , (2002)
Methanolic extract of whole plants of <i>Angelica decursiva</i>	 <p>Umbelliferone-6-carboxylic acid</p>	Zhao <i>et al.</i> , (2012)

earliest reports on synthetic coumarin derivatives appeared in 1992 wherein Maddi *et al.* (1992) have reported a series of substituted 3-(benzylideneamino)coumarins and their evaluation for anti-inflammatory activity at an oral dose of 100 mg/kg. The compounds 1 and 2 exhibited, respectively 75 and 60 % inhibitions of carrageenan-induced paw edema (CPE). These also showed significant analgesic activity in acetic acid-induced writhing model in mice.


Subsequently, Nicolaides *et al.* (1998) synthesized varied coumarin-4-carboxamidoximes and 4-oxadiazolyl coumarins. From these series, the compounds 3 and 4 produced maximum inhibition of CPE (more than 80 %), whereas the compounds 5 and 6 inhibited lipooxygenase with IC₅₀ value of 76 and 77 %, respectively. The study suggested an unsaturated substituent as an important feature at C-4 of the coumarin nucleus.



From a series of 2-oxo-2H-1-benzopyran-3-carboxamides, the compound 7 is reported to produce 54 %


reduce the O_2^- production. The study revealed the importance of an acetoxy group at C-7 in coumarin nucleus as its replacement decrease the activity (Mazzeia *et al.*, 2001). Potent anti-inflammatory activities of benzofuranyl and aryloxy derivatives of coumarins (10 and 11) (Ghate *et al.*, 2003) have further supported the importance of an unsaturated functional group at C-4 as discussed earlier for the compounds 3–6.

Cheng *et al.* (2004) have developed a series of carbamic acid esters of 7-coumarinol from which the compound 12 is reported as a moderate TNF- α inhibitor. Various modifications were carried out at C-3 and C-7 to enhance the activity. The *N,N*-diethyl carbamate and *N,N*-dimethyl thiocarbamate analogs are found to have activities higher than the *N,N*-dimethyl carbamate analog. Placement of a





inhibition in CPE and also found to be non-toxic at the higher dose levels (Bylov *et al.*, 1999). The unsymmetrically bis-coumarin derivatives (8 and 9) are found to possess protein kinase C inhibitory activity and capacity to

fluorine at *para*-position of the benzyl (13), replacement of benzyl with phenyl (14) or with pyridine (15) at C-3 greatly enhanced the TNF α inhibitory activity (IC_{50} 2.4, 0.32, and 0.45 μ M, respectively).




Nicolaidis *et al.* (2004) have synthesized and reported a series of Benzo[*l*]khellactone derivatives. Among these, compounds 16 and 17 exhibit the maximum activity with 59 % inhibition of CPE and 100 % inhibition of lipoxygenase. Kontogiorgis and Hadjipavlou-Litina (2004) have synthesized several coumarin derivatives possessing azomethine substituents at C-7 and evaluated for in vivo anti-inflammatory and in vitro antioxidant activities. Of these, compounds 18 and 19 exhibit 54–58 % inhibition of CPE, which suggests that the minimum requirement for in vivo and in vitro activities include a coumarin ring bearing a polar substitution at 7-position similarly as noted in various plant-derived coumarin derivatives. Subsequently, the same authors explored various Mannich bases at C-8 of 7-hydroxy coumarin and found compounds 20 and 21 to exhibit 75–77 % inhibition of CPE in comparison to 47 % inhibition by indomethacin. In addition, the compounds 21 and 22 inhibit LOX and exert good antioxidant activities (Kontogiorgis and Hadjipavlou-Litina, 2005).



Ghate *et al.* (2005) have synthesized various coumarinyl ethers exemplified by compounds 23 and 24. The benzofuranyl derivative (24) is reported to have analgesic and anti-inflammatory activities comparable with indomethacin. A chlorine substituent at C-6 further increased the activity. Fusion of coumarin nucleus with benzofurans through pyridine ring produces compounds with good anti-inflammatory, analgesic, and antimicrobial activities. Among these, compounds 25 and 26 show anti-inflammatory activity in a dose-dependent manner with maximum inhibition (97 %) at 300 mg/kg (Khan *et al.*, 2005). Taking thiocoumarins as lead inducible nitric oxide synthase (iNOS) inhibitor, Jackson *et al.* (2005) have synthesized many compounds among which compound 27 is found to have IC_{50} of 60 nM for iNOS.

Taking compound 28 (a quinoline derivative) as lead, various coumarin derivatives were developed by replacing 2-cyanoquinoline moiety with fluorophenyl coumarin and dioxabicyclooctanyl moiety with hexafluorocarbonyl. The resultant molecule (29) exhibited lower toxicity with increasing anti-inflammatory activity. Prodrugs of 29 synthesized by derivatization at C-2 of coumarin ring further increase the activity (Grimm *et al.*, 2006). In the continuing attempts to develop potent anti-inflammatory and antioxidant molecules, Kontogiorgis *et al.* (2006) have also synthesized a series of coumarin derivatives with 7-azomethine linkage. The compound 30 emerged as the most potent COX-1 inhibitor (78.6 % inhibition). Gacche *et al.* (2006) have synthesized coumarin Schiff bases (CSBs) possessing


different substituents and evaluated for in vitro anti-inflammatory activity through inhibition of β -glucuronidase. The SAR studies revealed that the presence of a nitro group and the overall steric effect of CSBs may be the contributing factors for the inhibition of β -glucuronidase. The compound 31 was reported to be the most potent with 39 % inhibition.



A polysubstituted coumarin derivative (32) has been reported as a potent anti-inflammatory with IC_{50} of 7.6 μ M against NO production in LPS-induced rat paw edema and to reduce hydroxyl radical production by 50 % (Lin *et al.*, 2006). The fluorescent zinc probes of coumarin exert anti-inflammatory activity via inhibition of soybean

carbostyryl and 6,8-dibromo substitution in the coumarin ring enhances the anti-inflammatory activity (Kalkhambkar *et al.*, 2007). A report on angularly fused coumarins revealed that though the in vitro antioxidant activity of such compounds (35) was low, the in vivo anti-inflammatory activity was good, and the gastrointestinal toxicity was significantly low (Symeonidis *et al.*, 2009). Sandeep *et al.*

(2009) have developed a series of widely substituted 7-methoxy-4-methyl-8-[5-(substituted aryl)isoxazol-3-yl]-coumarins wherein the compounds 36 and 37 are found to possess good anti-inflammatory activity with 72 and 68 % inhibitions of CPE, respectively. In addition, the compounds were also found to be potently antibacterial.




lipoxygenase (LOX) and antioxidant activity via a scavenging superoxide anion radical. The compound 33 is found as the most potent molecule from the series with 92.4 % LOX inhibition (Hadjipavlou-Litina *et al.*, 2007a).

Tricyclic molecules synthesized from two coumarin nuclei connected through thiazoles (34) as well as carbostyryl (1-aza coumarin) have been evaluated for in vivo analgesic and anti-inflammatory activities. The SAR studies revealed that a chlorine substituent at C-7 of the

Melagraki *et al.* (2009) have designed and synthesized various coumarin-3-carboxamides as well as coumarin-lipoic acid conjugates to develop novel hybrid molecules for treatment of human diseases attributed to free radical damage. The compounds 38 and 39 have emerged as the most promising agents exhibiting 100 % hydroxyl radical scavenging activity as well as potent CPE inhibitions (59 and 73 %, respectively). Bansal *et al.* (2009) have designed coumarin derivatives bearing 5-phenyloxathiazol-4-yl

moiety at C-4 of the nucleus on the basis of the pharmacological requirements for binding with p38 MAP kinase. The compound 40 showed anti-inflammatory activity (55.28 % inhibition) comparable with indomethacin (56.52 % inhibition). Superimposition of 40 with the lead p38 kinase inhibitors suggested that the activity may be due to a p38 MAP kinase inhibition. Replacement of oxathiadiazole nucleus with pyrazoline has led to another series of compounds among which the compound 41 proved useful for acute and chronic inflammation with 67.5 and 45.4 % inhibitions, respectively. These compounds also possess analgesic and antipyretic activities with minimum ulcerogenic index (Khode *et al.*, 2009). Reddy *et al.* (2010) have synthesized similar kind of derivatives with 3-coumarinyl moieties and found compound 42 exhibiting 66.5 % inhibition in acute inflammatory model in rats as compared to indomethacin (70.99 %).

than the non-PEGylated ones (Pandeya *et al.*, 2010). Among a series of 3-formyl chromones derivatives, the butanohydrazide derivative (44) has been reported to exhibit potent anti-inflammatory activity (80.78 % inhibition of CPE) higher than aspirin. Hence it can be explored as a novel drug to reduce inflammation (Khan *et al.*, 2010). Sandhya *et al.* (2011) have assessed the anti-inflammatory behavior of various coumarin analogs by automated docking studies using a protein–ligand complex constructed on the basis of X-ray structure of COX-2 bound with indomethacin through Molegro Virtual Docker program. The compound 45 emerged as the most active candidate from the series which is found to interact with the enzyme through eight hydrogen bonds (Fig. 2). These include hydrogen bonds of O-1 with Arg⁴⁴ (distance 3.10 and 3.03 Å) and with Arg⁴⁶⁹ (2.79 Å), of O-2 with Arg⁴⁶⁹ (3.16 Å), of ester oxygen with Ser⁴⁷¹ (2.58 Å) and Tyr¹²² (3.23 Å), of benzothiazole ring nitrogen



Roussaki *et al.* (2010) synthesized 3-aryl coumarin analogs and evaluated for antioxidant and LOX inhibitory activities. The compound 43 caused 86 % LOX inhibition and prevent lipid peroxidation. Evaluation of some PEGylated and non PEGylated 4-methyl and 4,8-dimethyl coumarin derivatives as anti-adhesion molecules for ICAM-1 (intercellular cell adhesion molecule) on human endothelial cells revealed that PEGylated derivatives are more active

with Asn⁴³ (3.38 Å) and of NH₂ with Lys⁴⁶⁸ (2.79 Å). These docking studies revealed that the coumarin oxygen is important for binding with Arg⁴⁴ amino acid. The presence of benzthiazole moiety at C-7 increases hydrogen bond formation and thus increases anti-inflammatory activity. The H-bonding involving ester oxygen at C-7 further supports the importance of a polar function at this position (–OH, –OR or –NH) as revealed earlier.






Fig. 2 A model of binding between compound 45 and COX-2 through hydrogen bonds shown as *green dotted lines* (Color figure online)



Coupling of variously substituted coumarins with variously substituted quinolinones through benzofuran nucleus is reported to yield compounds having in vitro anti-inflammatory activity. A chlorine substituent in quinolinone or coumarin moiety (46) enhances anti-inflammatory, analgesic, and antimicrobial activities (Kalkhambkar *et al.*, 2011). Timonen *et al.* (2011) have found 7-hydroxy coumarins derivatives inhibit iNOS expression (56 %), NO and IL-6 productions (82 %) in a dose-dependent manner. A phenyl ring at position C-4 (47) or a lipophilic substitution at C-3 further increases the activity. Exploration of polar functional groups around the coumarin nucleus has culminated in compound IMMLG5521 having significant anti-inflammatory activity through inhibition of vascular permeability and leukocyte transmigration (Li *et al.*, 2011). Upadhyay *et al.* (2011) have synthesized a series of 4-styrylcoumarins and explored for anti-inflammatory and anti-tubercular

activities. The compound bearing unsubstituted styryl group (48) has been found to possess potent IL-6 inhibitory activity (87 %). Substitution with nitro group at 3-position or with hydroxy group at 4-position of the styrylic phenyl slightly decreases the activity. The other substituents (halogens, alkyl, alkoxy, etc.) at all other positions significantly decrease the IL-6 inhibition. On the contrary, a methoxy group at 3-position of the styrylic phenyl (49) confers significant TNF α inhibitory activity (73 %). Recently, Sasidhara *et al.* (2011) have designed bis-coumarins as hybrid molecules by combining pharmacophores of coumarins as well as chalcones with an aim to obtain antioxidant-anti-inflammatory molecules. Of the various compounds in the series, only compound 50 exhibited the best anti-inflammatory activity though less than ibuprofen. However, it also exhibited potent antioxidant activity which provides an important lead in the synthesis of dual-acting drugs.






Fig. 3 Substituents explored at different positions (C-3 to C-8) of coumarin nucleus for anti-inflammatory activity

Structure–activity relationship

Many research groups have developed series of compounds to find appropriate functional groups at different positions (from C-3 to C-8) of coumarin nucleus for maximum anti-inflammatory activity. Hadjipavlou-Litina *et al.* (2007b) have studied various hydroxyaryl-substituted coumarin derivatives to develop a SAR and found a polar group at 5-/6-/7-position incurs LOX inhibitory activity on coumarin. These explorations of various functional groups around the coumarin nucleus are summarized in Fig. 3. A critical analysis of the data in Fig. 3 has helped in proposing SAR around the nucleus which shall enable the chemists to rationally design novel anti-inflammatory molecules. The salient features of the proposed SAR are as follows:

- In contrast to the naturally occurring coumarin molecules, most of the synthetic analogs are synthesized by substitutions at C-3 and C-4 of the nucleus. However, C-5 remains unexplored similarly as noted in plant-derived coumarins. Further, the nature of the substituent at C-7 and C-8 is broadly similar in both the synthetic as well plant-derived coumarins.
- An electron-rich hydrophobic group comprising nitrogen containing heterocycles such as indole, pyrimidine, and pyrazole at C-3 potentiates the anti-inflammatory activity.
- An unsaturated heterocyclic rings mainly containing oxygen and nitrogen is well tolerated at C-4.
- A chlorine or bromine at C-6 increases the activity.
- The carbamates and nitrogen-containing heterocycles at C-7 increase the activity by interacting with the receptor through hydrogen bonding.

Conclusions and perspectives

Coumarin-derived compounds (both of natural as well as synthetic origins) possess good to excellent anti-inflammatory

activity. Despite this, no such compound has made its way to the clinics. In this article, various reports on exploration of synthetically derived coumarin analogs for anti-inflammatory activity in the literature are critically studied to review the developments in the field in a chronological order. The purpose is to generate a SAR around the coumarin nucleus. The SAR has revealed the suitability of various functional groups or moieties at different positions of the nucleus. The position 5 is found relatively unexplored. Hence, selection of appropriate functional group at C-5 can lead to development of novel clinically useful anti-inflammatory molecules. Conjugation of the coumarin nucleus with lipoic acid has conferred both the antioxidant as well as anti-inflammatory activities which suggest that conjugation of the coumarin nucleus with other class of compounds can also produce hybrid molecules having multiple activities.

References

- Bahadır O, Citoglu GS, Ozbek H, Dall Acqua S, Hosek J, Smejkal K (2011) Hepatoprotective and TNF- α inhibitory activity of Zosima absinthifolia extracts and coumarins. *Fitoterapia* 82:454–459
- Bansal Y, Ratra S, Bansal G, Singh I, Aboul-Eneinc HY (2009) Design and synthesis of coumarin substituted oxathiadiazolone derivatives having anti-inflammatory activity possibly through p38 MAP kinase inhibition. *J Iran Chem Soc* 6(3):504–509
- Bhagwat SS (2009) Kinase inhibitors for the treatment of inflammatory and autoimmune disorders. *Purinergic Signal* 5:107–115
- Bylov IE, Vasylyev MV, Bilokin YV (1999) Synthesis and anti-inflammatory activity of N-substituted 2-oxo-2H-1-benzopyran-3-carboxamides and their 2-imino analogues. *Eur J Med Chem* 34:997–1001
- Cheng JF, Chen M, Wallace D, Tith S, Arrhenius T, Kashiwagi H, Ono Y, Ishikawa A, Sato H, Kozono T, Satoh H, Nadzan AM (2004) Discovery and structure–activity relationship of coumarin derivatives as TNF- α inhibitors. *Bioorg Med Chem Lett* 14:2411–2415
- Cronstein BN, Weissmann G (1995) Targets for anti-inflammatory drugs. *Annu Rev Pharmacol Toxicol* 35:449–462
- Curini M, Cravotto G, Epifano F, Giannone G (2006) Chemistry and biological activity of natural and synthetic prenyloxycoumarins. *Curr Med Chem* 13(2):199–222
- Dinarello CA (2010) Anti-inflammatory agents: present and future. *Cell* 140:935–950
- Feghali CA, Wright TM (1997) Cytokines in acute and chronic inflammation. *Front Biosci* 2:12–26
- Fylaktakidou KC, Hadjipavlou-Litina DJ, Litinas KE, Nicolaidis DN (2004) Natural and synthetic coumarin derivatives with anti-inflammatory/antioxidant activities. *Curr Pharm Des* 10(30):3813–3833
- Gacche RN, Gond DS, Dhole NA, Dawane BS (2006) Coumarin schiff-bases: as antioxidant and possibly anti-inflammatory agents. *J Enzyme Inhib Med Chem* 21(2):157–161
- Ghate M, Manohar D, Kulkarni V, Shobha R, Kattimani SY (2003) Synthesis of vanillin ethers from 4-(bromomethyl) coumarins as anti-inflammatory agents. *Eur J Med Chem* 38:297–302
- Ghate M, Kusanur RA, Kulkarni MV (2005) Synthesis and in vivo analgesic and anti-inflammatory activity of some biheterocyclic coumarin derivatives. *Eur J Med Chem* 40:882–887

- Grimm EL, Brideau C, Chauret N, Chan CC, Delorme D, Ducharme Y, Ethier D, Falguyet JP, Friesen RW, Guay J, Hamel P, Riendeau D, Soucy-Breau C, Tagari P, Girard Y (2006) Substituted coumarins as potent 5-lipoxygenase inhibitors. *Bioorg Med Chem Lett* 16:2528–2531
- Grivennikov S, Greten FR, Karin M (2010) Immunity, inflammation and cancer. *Cell* 140:883–899
- Hadjipavlou-Litina DJ, Kontogiorgis CA, Pontiki E, Dakanali M, Akoumianaki A, Katerinopoulos HE (2007a) Anti-inflammatory and antioxidant activity of coumarins designed as potential fluorescent zinc sensors. *J Enzyme Inhib Med Chem* 22(3):287–292
- Hadjipavlou-Litina DJ, Litinas KE, Kontogiorgis C (2007b) The anti-inflammatory effect of coumarin and its derivatives. *Curr Med Chem* 6(4):293–306
- Jackson SA, Sahni S, Lee L, Luo Y, Nieduzak TR, Liang G, Chiang Y, Collar N, Fink D, He W, Laoui A, Merrill J, Boffey R, Crackett P, Rees B, Wong M, Guilloteau JP, Mathieuc M, Rebello SS (2005) Design, synthesis and characterization of a novel class of coumarin-based inhibitors of inducible nitric oxide synthase. *Bioorg Med Chem* 13:2723–2739
- Kalkhambkar RG, Kulkarni GM, Shivkumar H, Rao RN (2007) Synthesis of novel triheterocyclic thiazoles as anti-inflammatory and analgesic agents. *Eur J Med Chem* 42:1272–1276
- Kalkhambkar RG, Aridoss G, Kulkarni GM, Bapset RM, Mudaraddi TY, Premkumar N, Jeong YT (2011) Synthesis and biological activities of novel ethers of quinolinone linked with coumarins. *Monatsh Chem* 142:305–315
- Kang KH, Kong CS, Seo Y, Kim MM, Kim SK (2009) Anti-inflammatory effect of coumarins isolated from *Corydalis heterocarpa* in HT-29 human colon carcinoma cells. *Food Chem Toxicol* 47:2129–2134
- Keating G, Kennedy RO (1997) The chemistry and occurrence coumarins. *Coumarins: biology, applications and mode of action*. Wiley, Chichester, pp 23–66
- Khan IA, Kulkarni MV, Gopal M, Shahabuddin MS, Sun CM (2005) Synthesis and biological evaluation of novel angularly fused polycyclic coumarins. *Bioorg Med Chem Lett* 15:3584–3587
- Khan KM, Ambreen N, Mughal UR, Jalil S, Perveen S, Choudhary MI (2010) 3-Formylchromones: potential anti-inflammatory agents. *Eur J Med Chem* 45:4058–4064
- Khode S, Maddi V, Aragade P, Palkar M, Ronad PK, Mamledesai S, Thippeswamy AHM, Satyanarayana D (2009) Synthesis and pharmacological evaluation of a novel series of 5-(substituted) aryl-3-(3-coumarinyl)-1-phenyl-2-pyrazolines as novel anti-inflammatory and analgesic agents. *Eur J Med Chem* 44:1682–1688
- Kontogiorgis CA, Hadjipavlou-Litina DJ (2004) Synthesis and biological evaluation of novel coumarin derivatives with a 7-azomethine linkage. *Bioorg Med Chem Lett* 14:611–614
- Kontogiorgis CA, Hadjipavlou-Litina DJ (2005) Synthesis and anti-inflammatory activity of coumarin derivatives. *J Med Chem* 48:6400–6408
- Kontogiorgis CA, Savvoglou K, Hadjipavlou-Litina DJ (2006) Antiinflammatory and antioxidant evaluation of novel coumarin derivatives. *J Enzyme Inhib Med Chem* 21(1):21–29
- Lacy A, Kennedy RO (2004) Studies on coumarins and coumarin-related compounds to determine their therapeutic role in the treatment of cancer. *Curr Pharm Des* 10:3797–3811
- Lake B (1999) Coumarin metabolism, toxicity and carcinogenicity: relevance for human risk assessment. *Food Chem Toxicol* 37:423–453
- Li ZP, Hu JF, Sun MN, Ji HJ, Zhao M, Wu DH, Li GY, Liu G, Chen NH (2011) Effect of compound IMMLG5521, a novel coumarin derivative, on carrageenan-induced pleurisy in rats. *Eur J Pharmacol* 661:118–123
- Lin CM, Huang ST, Lee FW, Kuoa HS, Lin MH (2006) 6-Acyl-4-aryl/alkyl-5, 7-dihydroxycoumarins as anti-inflammatory agents. *Bioorg Med Chem* 14:4402–4409
- Ling LY, Yu CL, Chia WC, Wen SL, Chen TK, Ching CW (2002) Effects of sphondin, isolated from *Heracleum laciniatum*, on IL-1 β -induced cyclooxygenase-2 expression in human pulmonary epithelial cells. *Life Sci* 72:21–199
- Lino CS, Taveira ML, Viana GSB, Matos FJA (1997) Analgesic and antiinflammatory activities of *Justicia pectoralis* Jacq and its main constituents: coumarin and umbelliferone. *Phytother Res* 11:211–215
- Maddi V, Raghu KS, Rao MNA (1992) Synthesis and anti-inflammatory activity of 3-(benzylideneamino)coumarins in rodents. *J Pharm Sci* 81:964–966
- Mazzeia M, Donderoa R, Sottofattoria E, Mellonib E, Minafrab R (2001) Inhibition of neutrophil O₂⁻ production by unsymmetrical methylene derivatives of benzopyrans: their use as potential anti-inflammatory agents. *Eur J Med Chem* 36:851–861
- Medzhitov R (2008) Origin and physiological roles of inflammation. *Nature* 454:428–435
- Medzhitov R (2011) Inflammation 2010: new adventures of an old flame cell. *Cell* 140:771–776
- Melagraki G, Afantitis A, Igglessi-Markopoulou O, Detsi A, Koufaki M, Kontogiorgis C, Hadjipavlou-Litina DJ (2009) Synthesis and evaluation of the antioxidant and anti-inflammatory activity of novel coumarin-3-aminoamides and their alpha-lipoic acid adducts. *Eur J Med Chem* 44:3020–3026
- Menghini L, Epifano F, Genovese S, Marcotullio MC, Sosa S, Tubaro A (2010) Anti-inflammatory activity of coumarins from *Ligusticum lucidum* Mill. subsp. *Cuneifolium* (Guss.) Tammara (Apiaceae). *Phytother Res* 24:1697–1699
- Nathan C (2002) Points of control of inflammation. *Nature* 420:846–852
- Nazari ZE, Ironshahi M (2011) Biologically active sesquiterpene coumarins from *Ferula* species. *Phytother Res* 25:315–323
- Nicolaides DN, Fylaktakidou KC, Litinas KE, Litina DH (1998) Synthesis and biological evaluation of several coumarin-4-carboxamidoxime and 3-(coumarin-4-yl)-1,2,4-oxadiazole derivatives. *Eur J Med Chem* 33:715–724
- Nicolaides DN, Gautam DR, Litinas KE, Hadjipavlou-Litina DJ, Fylaktakidou KC (2004) Synthesis and evaluation of the antioxidant and anti-inflammatory activities of some benzo[*l*]khellactone derivatives and analogues. *Eur J Med Chem* 39:323–332
- Pan R, Gao XH, Li Y, Xi YF, Dai Y (2010) Anti-arthritis effect of scopoletin, a coumarin compound occurring in *Erycibe obtusifolia* Benth stems, is associated with decreased angiogenesis in synovium. *Fundam Clin Pharmacol* 24:477–490
- Pandeya MK, Balwanib S, Sharmaa PK, Parmar VS, Ghosh B, Watterson AC (2010) Design, synthesis and anti-inflammatory evaluation of PEGylated 4-methyl and 4,8-dimethylcoumarins. *Eur J Pharm Sci* 39:134–140
- Pozharitskaya ON, Shikov AN, Makarova MN, Kosman VM, Faustova NM, Tesakova SV, Makarov VG, Galambosi B (2010) Anti-inflammatory activity of a HPLC fingerprinted aqueous infusion of aerial part of *Bidens tripartita* L. *Phyto-medicine* 17:463–468
- Reddy CPK, Goud VM, Sreenivasulu N, Prasad R (2010) Design, synthesis and chemical characterization of some novel coumarin compounds and evaluation of their biological activity. *Int J Pharma World Res* 1(2):1–19
- Roussaki M, Kontogiorgis CA, Hadjipavlou-Litina D, Hamilakis S, Detsi A (2010) A novel synthesis of 3-aryl coumarins and evaluation of their antioxidant and lipoxygenase inhibitory activity. *Bioorg Med Chem Lett* 20:3889–3892

- Sandeep G, Ranganath YS, Bhasker S, Rajkumar N (2009) Synthesis and biological screening of some novel coumarin derivatives. *Asian J Res Chem* 2(1):155–160
- Sandhya B, Giles D, Mathew V, Basavarajaswamy G, Abraham R (2011) Synthesis, pharmacological evaluation and docking studies of coumarin derivatives. *Eur J Med Chem* 46:4696–4701
- Sashidhara KV, Kumar M, Modukuri RK, Sonkar R, Bhatia G, Khanna AK, Rai S, Shukla R (2011) Synthesis and anti-inflammatory activity of novel biscoumarin–chalcone hybrids. *Bioorg Med Chem Lett* 21:4480–4484
- Sebban H, Courtois G (2006) NF- κ B and inflammation in genetic disease. *Biochem Pharmacol* 72:1153–1160
- Shoeb A, Randhir S, Popli SP (1973) Coumarins and alkaloids of *Aegle marmelos*. *Phytochemistry* 12:2071–2072
- Silvan AM, Abad MJ, Bermejo R, Villar A (1998) Effects of compounds extracted From *Santolina oblongifolia* on TXB2 release in human platelets. *Inflammopharmacology* 6:255–263
- Symeonidis T, Fylaktakidou KC, Hadjipavlou-Litina DJ, Litinas KE (2009) Synthesis and anti-inflammatory evaluation of novel angularly or linearly fused coumarins. *Eur J Med Chem* 44:5012–5017
- Timonen JM, Nieminen RM, Sareila O, Goulas A, Moilanen LJ, Haukka M, Vainiotalo P, Moilanen E, Aulaskari PH (2011) Synthesis and anti-inflammatory effects of a series of novel 7-hydroxycoumarin derivatives. *Eur Med Chem* 46:3845–3850
- Upadhyay K, Bavishi A, Thakrar S, Radadiya A, Vala H, Parekh S, Bhavsar D, Savant M, Parmar M, Adlakha P, Shah A (2011) Synthesis and biological evaluation of 4-styrylcoumarin derivatives as inhibitors of TNF- α and IL-6 with anti-tubercular activity. *Bioorg Med Chem Lett* 21:2547–2549
- Zhao D, Islam MN, Ahn BR, Jung HA, Kim BW, Choi JS (2012) In vitro antioxidant and anti-inflammatory activities of *Angelica decursiva*. *Arch Pharm Res* 35(1):179–192